Novartis vs Roche: Founders, CEOs and History
Novartis was founded in 1996 by Daniel Vasella, Alex Krauer and is led by Vasant Narasimhan. Roche was founded in 1896 by Fritz Hoffmann-La Roche and is led by Thomas Schinecker.
Company facts
Founders
Novartis
Daniel Vasella
Novartis was formed in December 1996 when Ciba-Geigy and Sandoz merged in a deal valued at roughly $27 billion, then among the largest corporate mergers on record.
Alex Krauer
Alex Krauer was the first chairman of Novartis, serving from the company's formation through the roughly $27 billion merger of Ciba-Geigy and Sandoz in 1996 until 1999, when the board named CEO Daniel Vasella to replace him as chairman.
Roche
Fritz Hoffmann-La Roche
Fritz Hoffmann-La Roche (1868-1920) founded F. Hoffmann-La Roche & Co. in Basel on 1 October 1896, at age 28.
CEOs and their tenures
Novartis
- Joseph Jimenez2010–2018
Chief Executive Officer
Chief executive of Novartis from 2010 until January 31, 2018, when Vas Narasimhan succeeded him.
Source - Vas Narasimhan2018–present
Chief Executive Officer
Narasimhan, a physician who previously led global drug development, became CEO on February 1, 2018.
Source - Giovanni Caforio2025–present
Chair of the Board
Former Bristol Myers Squibb CEO who succeeded Joerg Reinhardt as Novartis chair at the March 2025 AGM.
Source - Mukul Mehta2026–present
Chief Financial Officer
Succeeded Harry Kirsch as CFO on March 16, 2026.
Source
Roche
- Severin Schwan2008–2023
Chief Executive Officer
Led Roche for 14 years; handed over to Thomas Schinecker in March 2023 and became chairman.
Source - Thomas Schinecker2023–present
Chief Executive Officer
Under Schinecker, Roche returned to growth after the COVID testing decline: 2025 sales rose 7% at constant rates to ~$73.8 billion (CHF 61.5 billion) and 12 late-stage studies read out positively that year.
Source
Timeline: Novartis and Roche side by side
1859Novartis
Founding of Ciba
Silk dyer Alexander Clavel began producing the synthetic dye fuchsine in Basel, Switzerland, marking the origin of Ciba, part of the Ciba-Geigy half of the Novartis merger.
1886Novartis
Founding of Sandoz
Alfred Kern and Edouard Sandoz founded the chemical company Kern & Sandoz in Basel, establishing the second half of the corporate lineage that would eventually merge to form Novartis.
1896Roche
F. Hoffmann-La Roche Founded in Basel
Fritz Hoffmann-La Roche founds the enterprise in Basel, Switzerland, pioneering mass-manufactured, chemically standardized prescription pharmaceuticals.
1898Roche
Commercial Breakthrough with Sirolin
Roche launches non-prescription cough syrup Sirolin, achieving widespread international distribution and financing early clinical laboratories.
1934Roche
First Industrial Synthesis of Vitamin C
Roche becomes the first company to mass-produce synthetic Vitamin C (Redoxon) at industrial scale, anchoring decades of high-margin global cash flow.
1963Roche
Launch of Valium (Diazepam)
Roche introduces Valium, which becomes the world's most widely prescribed psychotropic medication and establishes global pharmaceutical leadership.
1968Roche
Establishment of Roche Diagnostics
Roche launches its dedicated diagnostic division, laying the foundation to become the world's preeminent in-vitro diagnostics (IVD) provider.
1996Novartis
Merger of Ciba-Geigy and Sandoz
Ciba-Geigy and Sandoz completed their merger in December 1996, a deal valued at roughly $27 billion, creating Novartis AG.
2006Novartis
Acquisition of Chiron Corporation
Novartis acquired the US biotechnology company Chiron Corporation for $5.1 billion, significantly expanding its vaccine and oncology franchises.
2009Roche
Full Acquisition of Genentech for $46.8 Billion
Roche completes its historic $46.8 billion buyout of American biotechnology pioneer Genentech, securing market leadership in oncology biologics.
2010Novartis
Acquisition of Alcon
Novartis completed the acquisition of the remaining stake in Alcon, the world's largest eye care company, for approximately $28 billion, creating a dominant position in ophthalmology.
2015Novartis
DOJ Settlement
Novartis paid $390 million to resolve US allegations that it gave kickbacks to specialty pharmacies to promote Exjade and Myfortic.
2018Novartis
Vas Narasimhan Appointed CEO
Vas Narasimhan became CEO at age 41, one of the youngest leaders of a major pharmaceutical company, initiating a strategic review that would eventually lead to the Sandoz spin-off.
2018Roche
Foundation Medicine & Flatiron Health Acquisitions
Roche acquires Foundation Medicine and Flatiron Health, integrating real-world oncology data analytics and genomic profiling into personalized healthcare.
2023Novartis
Acquisition of Chinook Therapeutics
Novartis acquired Chinook Therapeutics for $3.2 billion upfront plus $300 million in milestones, securing late-stage assets for rare kidney diseases.
2023Novartis
Spin-off of Sandoz
On October 4, 2023, Novartis completed the 100% spin-off of its Sandoz generics division, transforming into a pure-play innovative medicines company.
2024Novartis
Acquisition of MorphoSys
Novartis acquired German biotech MorphoSys for about EUR 2.7 billion ($2.9 billion), adding the investigational myelofibrosis drug pelabresib.
2025Novartis
FY2025 Financial Results
Novartis reported FY2025 net sales of $54.5 billion, up 8%, with a core operating margin above 40% and free cash flow of $17.6 billion.
2025Novartis
Entresto Generic Entry
US generic versions of Entresto, Novartis's largest product, launched in 2025, starting the steepest patent cliff in the company's post-Sandoz history.
2025Roche
Group Sales Reach CHF 61.5 Billion
Under CEO Thomas Schinecker, Roche delivers group sales of ~$73.8 billion (CHF 61.5 billion), driven by ~$57.2B (CHF 47.7B) in Pharmaceuticals and ~$16.6B (CHF 13.8B) in Diagnostics.
2026Novartis
Avidity Biosciences Acquisition Closes
On February 27, 2026, Novartis completed its roughly $12 billion acquisition of Avidity Biosciences, adding antibody-oligonucleotide conjugates for DM1, Duchenne and FSHD.
2026Novartis
HARBOR Phase 3 Miss
In September 2026, del-desiran missed the primary endpoint of the 159-patient Phase 3 HARBOR trial in myotonic dystrophy type 1, and NVS shares fell about 12.5% in pre-market trading.
Acquisitions
Novartis
- Avidity Biosciences2026$12B
- MorphoSys AG2024$2.9B
- Chinook Therapeutics2023$3.5B
- The Medicines Company2020$9.7B
- Advanced Accelerator Applications2018$3.9B
- Chiron Corporation2006$5.1B
Roche
- PathAI2026$1.1B
- 89bio2025$3.5B
- Telavant2023$7.1B
- Carmot Therapeutics2023$2.7B
- Foundation Medicine2018$2.4B
- ForSight VISION42017Undisclosed
Questions about Novartis vs Roche
Who is the CEO of Novartis AG and F. Hoffmann-La Roche AG?
Novartis AG is led by Vasant Narasimhan and F. Hoffmann-La Roche AG is led by Thomas Schinecker. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Novartis AG founded vs F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG was founded in 1896 — 100 years before Novartis AG, which was founded in 1996. F. Hoffmann-La Roche AG's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Novartis AG.
How many employees does Novartis AG have compared to F. Hoffmann-La Roche AG?
Novartis AG employs approximately 75,267 people, while F. Hoffmann-La Roche AG employs approximately 112,774. F. Hoffmann-La Roche AG has the larger workforce at 112,774 employees, compared to Novartis AG's 75,267. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Novartis AG and F. Hoffmann-La Roche AG headquartered?
Both Novartis AG and F. Hoffmann-La Roche AG are headquartered in Switzerland, meaning they operate under the same primary regulatory and tax environment.
Who founded Novartis AG and F. Hoffmann-La Roche AG?
Novartis AG was founded by Daniel Vasella, Alex Krauer. F. Hoffmann-La Roche AG was founded by Fritz Hoffmann-La Roche.
Which company has a longer operating history — Novartis AG or F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG has been operating for approximately 130 years, making it the more established of the two companies. Novartis AG has been in operation for around 30 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Novartis vs Roche overview